All In Biotech

Drug Trial Radar · NCT00297102

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study

Last checked: Nov 19, 2026Latest source record: Jan 16, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,523 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,523

Actual

Start

Feb 2006

Primary completion

Jul 2008

Study completion Sep 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 28, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast. For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • RoflumilastDrug

    500 mcg, once daily, oral administration in the morning

  • PlaceboDrug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)Time frame: Change from baseline over 52 weeks of treatment
  2. COPD Exacerbation Rate (Moderate or Severe)Time frame: 52 weeks treatment period

Locations

179 sites in 11 countries. Site status is shown where the registry gives one.

  • Altana Pharma/Nycomed Investigational Site

    Fullerton, California

  • Altana Pharma/Nycomed Investigational Site

    Los Angeles, California

  • Altana Pharma/Nycomed Investigational Site

    Los Angeles, California

  • Altana Pharma/Nycomed Investigational Site

    Palmdale, California

  • Altana Pharma/Nycomed Investigational Site

    Rancho Mirage, California

  • Altana Pharma/Nycomed Investigational Site

    San Diego, California

  • Altana Pharma/Nycomed Investigational Site

    Bay Pines, Florida

  • Altana Pharma/Nycomed Investigational Site

    Miami, Florida

  • Altana Pharma/Nycomed Investigational Site

    Panama City, Florida

  • Altana Pharma/Nycomed Investigational Site

    Atlanta, Georgia

  • Altana Pharma/Nycomed Investigational Site

    Marietta, Georgia

  • Altana Pharma/Nycomed Investigational Site

    Hines, Illinois

  • Altana Pharma/Nycomed Investigational Site

    South Bend, Indiana

  • Altana Pharma/Nycomed Investigational Site

    Lebanon, Kentucky

  • Altana Pharma/Nycomed Investigational Site

    Metairie, Louisiana

  • Altana Pharma/Nycomed Investigational Site

    New Orleans, Louisiana

  • Altana Pharma/Nycomed Investigational Site

    Slidell, Louisiana

  • Altana Pharma/Nycomed Investigational Site

    Sunset, Louisiana

  • Altana Pharma/Nycomed Investigational Site

    Bangor, Maine

  • Altana Pharma/Nycomed Investigational Site

    Baltimore, Maryland

  • Altana Pharma/Nycomed Investigational Site

    North Dartmouth, Massachusetts

  • Altana Pharma/Nycomed Investigational Site

    Edina, Minnesota

  • Altana Pharma/Nycomed Investigational Site

    Minneapolis, Minnesota

  • Altana Pharma/Nycomed Investigational Site

    Chesterfield, Missouri

  • Altana Pharma/Nycomed Investigational Site

    St Louis, Missouri

  • Altana Pharma/Nycomed Investigational Site

    Billings, Montana

  • Altana Pharma/Nycomed Investigational Site

    Missoula, Montana

  • Altana Pharma/Nycomed Investigational Site

    Lincoln, Nebraska

  • Altana Pharma/Nycomed Investigational Site

    Omaha, Nebraska

  • Altana Pharma/Nycomed Investigational Site

    Reno, Nevada

  • Altana Pharma/Nycomed Investigational Site

    Cherry Hill, New Jersey

  • Altana Pharma/Nycomed Investigational Site

    Springfield, New Jersey

  • Altana Pharma/Nycomed Investigational Site

    New York, New York

  • Altana Pharma/Nycomed Investigational Site

    Winston-Salem, North Carolina

  • Altana Pharma/Nycomed Investigational Site

    Cincinnati, Ohio

  • Altana Pharma/Nycomed Investigational Site

    Columbus, Ohio

  • Altana Pharma/Nycomed Investigational Site

    Toledo, Ohio

  • Altana Pharma/Nycomed Investigational Site

    Youngstown, Ohio

  • Altana Pharma/Nycomed Investigational Site

    Lake Oswego, Oregon

  • Altana Pharma/Nycomed Investigational Site

    Philadelphia, Pennsylvania

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.